Orion saw the highest growth of 1.99% in patent filings in May and 1.32% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 1.66% and grants by 1.32%. GlobalData’s DataBook provides a comprehensive analysis of Orion‘s patent filings and grants. Buy the databook here.
Orion has been focused on protecting inventions in United States(US) with eight publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 44% filings and 20% grants. The United States(US), Hungary(HU), Australia(AU), and Spain(ES) patent Office are among the top ten patent offices where Orion is filings its patents. Among the top granted patent authorities, Orion has 40% of its grants in Spain(ES), 40% in Poland(PL) and 20% in United States(US).
Roche and Johnson & Johnson could be the strongest competitors for Orion
Patents related to genomics and cell & gene therapy lead Orion's portfolio
Orion has the highest number of patents in genomics followed by, cell & gene therapy. For genomics, nearly 75% of patents were filed and no patents were granted in Q2 2024.
Prostate cancer related patents lead Orion portfolio followed by breast cancer, and packaging
Orion has highest number of patents in prostate cancer followed by breast cancer, packaging, emesis (vomiting), and dementia.
For comprehensive analysis of Orion's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.